



(12) Translation of
European patent specification

(11) NO/EP 3536346 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 51/08 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.03.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.10.28
(86)	European Application Nr.	19164889.8
(86)	European Filing Date	2012.08.23
(87)	The European Application's Publication Date	2019.09.11
(30)	Priority	2011.08.31, DK, PA201100654
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2750717, 2012.08.23
(73)	Proprietor	Somscan ApS, Marielystvej 11, 2000 Frederiksberg, Danmark
(72)	Inventor	KJAER, Andreas, Marielystvej 11, 2000 Frederiksberg, Danmark KNIGGE, Ulrich, Blegdamsvej 9, 2100 Copenhagen Ø, Danmark HØJGAARD, Liselotte, Blegdamsvej 9, 2100 Copenhagen Ø, Danmark RASMUSSEN, Palle, Frederiksborgvej 399, 4000 Roskilde, Danmark
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54)	Title	PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS
(56)	References Cited:	A. PFEIFER ET AL: "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients", THE JOURNAL OF NUCLEAR MEDICINE, vol. 56, no. 6, 7 May 2015 (2015-05-07), pages 847-854, XP055414823, US ISSN: 0161-5505, DOI: 10.2967/jnumed.115.156539 R. SRIRAJASKANTHAN ET AL: "The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy", THE JOURNAL OF NUCLEAR MEDICINE, vol. 51, no. 6, 19 May 2010 (2010-05-19), pages 875-882, XP055414643, US ISSN: 0161-5505, DOI: 10.2967/jnumed.109.066134 A. PFEIFER ET AL: "Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study", THE JOURNAL OF NUCLEAR MEDICINE, vol. 53, no. 8, 10 July 2012 (2012-07-10), pages 1207-1215, XP055163911, ISSN: 0161-5505, DOI: 10.2967/jnumed.111.101469 HIROFUMI HANAOKA ET AL: "Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors", ANNALS OF NUCLEAR MEDICINE, vol. 23, no. 6, 6 June 2009 (2009-06-06), pages 559-567, XP055147723,


ISSN: 0914-7187, DOI: 10.1007/s12149-009-0274-0

Jason S. Lewis ET AL: "Comparative Dosimetry of Copper-64 and Yttrium- 90-Labeled Somatostatin Analogs in a Tumor -Bearing Rat Model", CANCER BIOTHE RAPHY& RADIOPHARMACEUTICALS Volume, 1 January 2000 (2000 -01-01), pages 593-604, XP055164025, Retrieved from the Internet: URL:<http://online.liebertpub.com/doi/pdfplus/10.1089/cbr.2000.15.593> [retrieved on 2015-01-21]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Anvendelse av en sammensetning omfattende en forbindelse av formel 1
formel I



^{64}Cu -DOTA-TATE;

eller et farmasøytisk akseptabelt salt derav,

som en PET-sporer i en fremgangsmåte for radiografisk avbildning av en
nevroendokrin tumor hos en menneskelig pasient.

2. Anvendelse ifølge krav 1, hvori sammensetningen videre omfatter gentisinsyre.
3. Anvendelse ifølge krav 1, hvori sammensetningen videre omfatter
natriumacetat.